MX2017017081A - Polimorfo de macrociclo de diarilo. - Google Patents

Polimorfo de macrociclo de diarilo.

Info

Publication number
MX2017017081A
MX2017017081A MX2017017081A MX2017017081A MX2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A MX 2017017081 A MX2017017081 A MX 2017017081A
Authority
MX
Mexico
Prior art keywords
polymorph
macrocycle
diaryl
polymorphs
mammals
Prior art date
Application number
MX2017017081A
Other languages
English (en)
Inventor
W Rogers Evan
J Cui Jingrong
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of MX2017017081A publication Critical patent/MX2017017081A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Esta divulgación se refiere a los polimorfos de (7S,13R,)-11-fluoro-7,13-dimetil-6,7,13,14-tetrahidro-1,15-etenop irazolo[4,3-f] [1,4,8,10]benzoxatriazaciclotridecin-4(5H)-ona que son útiles en el tratamiento de enfermedades, tales como cáncer, en mamíferos. Esta divulgación también se relaciona con composiciones que incluyen estos polimorfos y a métodos para usar dichas composiciones en el tratamiento de enfermedades, tales como el cáncer, en mamíferos, especialmente en los seres humanos.
MX2017017081A 2015-07-06 2016-07-05 Polimorfo de macrociclo de diarilo. MX2017017081A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US201562218672P 2015-09-15 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Publications (1)

Publication Number Publication Date
MX2017017081A true MX2017017081A (es) 2018-08-16

Family

ID=57685592

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017017081A MX2017017081A (es) 2015-07-06 2016-07-05 Polimorfo de macrociclo de diarilo.
MX2021008145A MX2021008145A (es) 2015-07-06 2017-12-20 Polimorfo de macrociclo de diarilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008145A MX2021008145A (es) 2015-07-06 2017-12-20 Polimorfo de macrociclo de diarilo.

Country Status (16)

Country Link
US (4) US10294242B2 (es)
EP (1) EP3319969B1 (es)
JP (2) JP6917974B2 (es)
KR (1) KR102623734B1 (es)
CN (2) CN108026108B (es)
AU (1) AU2016289454B2 (es)
BR (1) BR112018000297A2 (es)
CA (1) CA2990020C (es)
FI (1) FI3319969T3 (es)
HK (1) HK1254492A1 (es)
IL (2) IL256443B (es)
LT (1) LT3319969T (es)
MX (2) MX2017017081A (es)
RU (1) RU2765181C2 (es)
WO (1) WO2017007759A1 (es)
ZA (1) ZA201708436B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA121206C2 (uk) 2014-01-24 2020-04-27 Турнінґ Поінт Терапьютикс, Інк. Діарильні макроцикли як модулятори протеїнкіназ
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
EP3733187A1 (en) * 2015-07-21 2020-11-04 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技(苏州)有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
UA126158C2 (uk) 2017-07-28 2022-08-25 Тьорнінґ Поінт Терапьютикс, Інк. Макроциклічні сполуки і їх використання
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
WO2019201131A1 (zh) * 2018-04-16 2019-10-24 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
MX2021004538A (es) 2018-10-22 2021-09-10 Esker Therapeutics Inc Inhibidores de tyk2 y sus usos.
US20220235070A1 (en) 2019-05-21 2022-07-28 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
PE20220135A1 (es) * 2019-06-19 2022-01-27 Turning Point Therapeutics Inc Polimorfos de un inhibidor de cinasas macrociclicas
BR112022010278A2 (pt) 2019-11-27 2022-10-04 Turning Point Therapeutics Inc Terapia combinada que envolve compostos macrocíclicos de diarila
IL293208A (en) 2019-11-27 2022-07-01 Turning Point Therapeutics Inc Combination therapy involving diaryl macrocyclic compounds
EP4114530A4 (en) * 2020-03-02 2024-04-17 Turning Point Therapeutics Inc THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS
CN113620974B (zh) 2020-05-08 2023-01-31 山东轩竹医药科技有限公司 大环类酪氨酸激酶抑制剂的晶型及其制备方法
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9403639D0 (en) * 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
AU2009288021B2 (en) 2008-09-08 2015-06-18 Merck Patent Gmbh Macrocyclics pyrimidines as Aurora kinase inhibitors
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
ES2588504T3 (es) 2008-10-22 2016-11-03 Array Biopharma, Inc. Compuestos de pirazolo[1,5-a]pirimidina sustituidos como compuestos intermedios en la síntesis de inhibidores de TRK quinasa
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
SG10201506591TA (en) * 2010-05-20 2015-09-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
KR20140059236A (ko) 2011-08-19 2014-05-15 머크 샤프 앤드 돔 코포레이션 Hcv 프로테아제 억제제의 결정 형태
HUE027318T2 (en) 2011-09-30 2016-10-28 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
MX350844B (es) 2012-03-06 2017-09-22 Pfizer Derivados macrocíclicos para el tratamiento de enfermedades proliferativas.
JP6418949B2 (ja) * 2012-03-09 2018-11-07 レクシコン ファーマシューティカルズ インコーポレイテッド イミダゾ[1,2−b]ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10497029B2 (en) * 2013-10-21 2019-12-03 Disney Enterprises, Inc. Systems and methods for facilitating brand integration within online content and promoting that online content
UA121206C2 (uk) 2014-01-24 2020-04-27 Турнінґ Поінт Терапьютикс, Інк. Діарильні макроцикли як модулятори протеїнкіназ
ES2864839T3 (es) * 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
EP3733187A1 (en) * 2015-07-21 2020-11-04 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer

Also Published As

Publication number Publication date
HK1254492A1 (zh) 2019-07-19
FI3319969T3 (fi) 2024-06-13
RU2765181C2 (ru) 2022-01-26
CN108026108A (zh) 2018-05-11
JP6917974B2 (ja) 2021-08-11
RU2018104269A (ru) 2019-08-06
EP3319969A4 (en) 2019-07-03
CA2990020A1 (en) 2017-01-12
MX2021008145A (es) 2021-08-11
KR20180026480A (ko) 2018-03-12
EP3319969B1 (en) 2024-04-03
US20180194777A1 (en) 2018-07-12
CA2990020C (en) 2024-02-27
EP3319969A1 (en) 2018-05-16
US20230295184A1 (en) 2023-09-21
US20190233437A1 (en) 2019-08-01
US20210094974A1 (en) 2021-04-01
JP2018529633A (ja) 2018-10-11
US10294242B2 (en) 2019-05-21
IL283184B2 (en) 2023-06-01
LT3319969T (lt) 2024-06-10
IL283184A (en) 2021-06-30
AU2016289454B2 (en) 2020-07-09
BR112018000297A2 (pt) 2018-09-04
AU2016289454A1 (en) 2018-01-04
RU2018104269A3 (es) 2019-12-17
WO2017007759A1 (en) 2017-01-12
JP2021119151A (ja) 2021-08-12
CN108026108B (zh) 2021-06-22
JP7212713B2 (ja) 2023-01-25
CN113354653A (zh) 2021-09-07
IL256443B (en) 2021-05-31
KR102623734B1 (ko) 2024-01-10
IL256443A (en) 2018-02-28
ZA201708436B (en) 2021-03-31

Similar Documents

Publication Publication Date Title
MX2021008145A (es) Polimorfo de macrociclo de diarilo.
MX2018000718A (es) Macrociclos de diarilo quirales y usos de los mismos.
MX2023010042A (es) Polinucleotidos moduladores.
IL264049A (en) Compounds, preparations and methods for treating the disease
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
IL264156A (en) Compounds, preparations and methods for treating the disease
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MY193728A (en) Muscarinic receptor agonists
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
WO2017214170A3 (en) Baff-r antibodies and uses thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases